Could Genocea Biosciences, Inc. (GNCA) Crash Even More? The Stock Just Made 1 Year Low

July 16, 2018 - By Lisa Delgado

Genocea Biosciences, Inc. (NASDAQ:GNCA) Logo

The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) hit a new 52-week low and has $0.72 target or 8.00 % below today’s $0.78 share price. The 6 months bearish chart indicates high risk for the $67.52M company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $0.72 price target is reached, the company will be worth $5.40 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 3.88% or $0.0315 during the last trading session, reaching $0.7798. About 377,201 shares traded. Genocea Biosciences, Inc. (NASDAQ:GNCA) has declined 84.29% since July 16, 2017 and is downtrending. It has underperformed by 96.86% the S&P500.

Analysts await Genocea Biosciences, Inc. (NASDAQ:GNCA) to report earnings on August, 8. They expect $-0.14 earnings per share, up 74.07 % or $0.40 from last year’s $-0.54 per share. After $-0.14 actual earnings per share reported by Genocea Biosciences, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Genocea Biosciences, Inc. (NASDAQ:GNCA) Ratings Coverage

Among 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Genocea Biosciences had 6 analyst reports since February 6, 2018 according to SRatingsIntel. Cantor Fitzgerald initiated the shares of GNCA in report on Monday, March 5 with “Buy” rating. H.C. Wainwright maintained the shares of GNCA in report on Thursday, April 19 with “Buy” rating. The firm earned “Buy” rating on Tuesday, February 6 by Needham. H.C. Wainwright maintained the stock with “Buy” rating in Monday, April 30 report.

Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company has market cap of $67.52 million. The firm uses AnTigen Lead Acquisition System , its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. It currently has negative earnings. The Company’s lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections.

Genocea Biosciences, Inc. (NASDAQ:GNCA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.